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Pneumococcal vaccine in patients with renal disease. Polyvalent pneu-
mococcal vaccine was administered to 7 patients with chronic renal
failure, 14 patients on chronic hemodialysis, 14 splenectomized and 11
nonspienectomized renal allograft recipients, and 14 normal adults.
Ninety-three percent of normal subjects had at least a twofold rise in
serum antibody concentration after vaccination, with a geometric mean
antibody concentration after vaccination greater than 200 ng N/mI. The
response to vaccination in hemodialysis patients was similar to that in
normal persons. Renal failure patients showed impaired antibody
synthesis in response to the vaccine, with 43% achieving at least a
twofold rise in antibody concentration. Allograft recipients had a lower
antibody concentration before as well as after vaccination, and among
splenectomized recipients the prevaccination antibody concentration
was directly related to the interval between transplantation and anti-
body determination. But, 80% of allograft recipients achieved a twofold
rise in antibody concentration after vaccination. The response to
pneumococcal vaccine was quantitatively similar for splenectomized
and nonsplenectomized allograft recipients.
Vaccin pneumococcique chez les malades atteints d'insuffisance rénale.
Du vaccin pneumococcique polyvalent a été administré a 7 malades
atteints d'insuffisance rénale chronique, 14 malades en hémodialyse
chronique, 14 receveurs d'allogreffe rénale splénectomisés et 11 non
splénectomisés, et 14 adultes normaux. Quatre vingt treize pour cent
des sujets normaux ont eu au moms un doublement de Ia concentration
d'anticorps sériques après Ia vaccination avec une moyenne géomé-
trique de concentration superieure a 200 ng N/mI. La réponse des
malades en hemodialyse chronique a été semblable a celle des sujets
normaux. Les malades en insuffisance rénale ont montré une alteration
de Ia synthese d'anticorps en réponse a Ia vaccination, 43% d'entre eux
ont atteint un doublement de Ia concentration d'anticorps. Les rece-
veurs de greffe avaient une concentration d'anticorps plus faible, avant
aussi bien qu'après Ia vaccination, et parmis les receveurs splénecto-
misés Ia concentration prévaccinale était directement liée a l'intervalle
entre Ia transplantation et Ia determination de la concentration d'anti-
corps. Quatre-vingt pour cent des receveurs de greffe, cependant, ont
eu un doublement de Ia concentration d'anticorps après vaccination. La
rdponse au vaccin pneumococcique était quantitativement similaire
pour les receveurs splénectomisés et non splénectomisés.
Vaccination with multivalent pneumococcal capsular poly-
saccharide vaccines provides effective prophylaxis against bac-
teremic pneumococcal disease and putative pneumococcal
pneumonia in adults [1]. The vaccine has been recommended
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for patients 50 years of age and older and those with chronic
systemic illnesses [2]. Among the latter, the vaccine has been
recommended for patients with anatomical or functional as-
plenia because of their susceptibility to overwhelming pneumo-
coccal septicemia [3]. Patients with chronic renal failure should
be considered candidates for pneumococcal vaccine because of
their high incidence of pneumonia and impaired host defenses
14, 5]. Streptococcus pneumoniae caused 53% of community-
acquired pulmonary infections and 20% of septicemias in a large
group of patients on chronic hemodialysis [61. Renal allograft
recipients are also at high risk for pneumococcal infections and
in particular pneumococcal septicemia possibly because they
are maintained on immunosuppressive therapy and frequently
have splenectomy as a preparative step to transplantation [7—9].
This investigation evaluated the adequacy of the anticapsular
antibody response to pneumococcal vaccine in patients with
chronic renal failure, patients on chronic hemodialysis, and in
renal allograft recipients and identified factors that might affect
this response. Vaccination was also used to study the humoral
immune competence of these patients.
Methods
Tetradecavalent pneumococcal capsular polysaccharide vac-
cine was administered to 7 patients with chronic renal failure,
14 patients maintained on chronic hemodialysis, 14 splenecto-
mized and 11 nonsplenectomized renal allograft recipients, and
14 normal adult volunteers (Table 1). The etiology of renal
disease in these patients included diabetes mellitus, chronic
glomerulonephritis, chronic pyelonephritis, polycystic kidney
disease, nephrosclerosis, systemic lupus erythematosus, and
Wegener's granulomatosis (Table 2). Informed consent was
obtained from all participants. The vaccine was obtained from
Lederle Corporation, New York, via the Bacterial Vaccines
Program, National Institute of Allergy and Infectious Diseases,
and was administered s.c. in the upper arm in a dose of 0.5 ml.
It contained 50 g of each of the following pneumococcal
capsular polysaccharides: types 1, 3, 4, 6A, 6B, 7, 8, 9, 12, 14,
18, 19, 20, 23 (Danish nomenclature). Serum samples were
obtained from each patient before vaccination and 3 to 6 weeks
after vaccination. All serum samples were stored at —70° C and
simultaneously tested for 12 of the 14 types of specific anticap-
sular antibodies using a sensitive radioimmunoassay [10]. Anti-
body concentrations were expressed as nanograms of antibody
nitrogen per milliliter (ng N/mI).
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Table 1. Clinical parameters
Patient group
No. of Age range (mea
patients yr
n) Sex Serum creatininea
MIF mg/dl
Normal
Chronic renal failure
Chronic hemodialysis
Splenectomized allograft recipients
Nonsplenectomized allograft recipients
14 20 to 49(29)
7 29 to 65(46)
14 27 to 76(49)
14 15 to 63(42)
11 26 to 56(38)
10/5 —
3/4 6.1 2.3
5/9 9.3 2.3
5/9 1.2 0.3
7/4 1.4 0.3
Values are the means SEM.
Table 2. Etiology of renal disease
Disease
Chronic
renal
failure
Chronic
hemodialysis
Allograft recipients
Splenectomized Nonsplenectomized
Diabetes
Chronic glomerulonephritis
Chronic pyelonephritis
Polycystic kidney disease
Nephrosclerosis
Other
2
—
3
2
—
—
2
1
1
1
5
4
3 7
5 2
2 —
3 —
1 1
—
Fig. 1. Relationship between the geometric mean (GM) antibody
concentration before and after vaccination and the fold rise in antibody
concentration after vaccination. Symbols are A for normal subjects;
for chronic renal failure; U for chronic hemodialysis; 0 for splenecto-
mized renal allograft recipients; and • for nonsplenectomized renal
allograft recipients.
All patients, except normal controls, had determinations of
serum creatinine before vaccination (Table 1). In addition,
serum creatinine was determined after vaccination in renal
allograft recipients. Allograft recipients were vaccinated 3 to
118 months after renal transplantation during an outpatient
followup visit. Chronic hemodialysis patients had been main-
tained on hemodialysis from 1 to 42 months before they were
vaccinated, and serum creatinine in these patients was mea-
sured immediately before hemodialysis at the time of vaccina-
tion.
All renal allograft recipients received immunosuppressive
therapy after transplantation. Therapy included antilymphocyte
globulin (ALG) (30 mg/kg/day, i.v.) for 2 weeks, methylpredni-
solone (20 mg/kg/day, i.v.) for 3 days, azathioprine (5 mgI
kg/day, tapered to a maintenance dosage of 2.0 to 2.5 mg/kg/day
by one week), prednisone (2 mg/kg/day tapered to 0.5
mg/kg/day by 2 months and 0.25 mg/kg/day by 1 year), and local
allograft irradiation (150 rads every other day) for 3 days.
Rejection episodes were treated with local graft irradiation,
increased prednisone dosage to 2 mg/kg/day and, in some
instances, administration of methylprednisolone at a dosage of
20 mg/kg/day i.v. for 3 days. At the time of vaccination,
splenectomized allograft recipients were taking a mean dosage
of azathioprine of 2.06 mg/kg/day (range, 1.1 to 2.5 mg/kg/day)
and prednisone dosage of 0.3 mg/kg/day (range, 0.13 to 0.49
mg/kg/day). The dosages of these drugs in nonsplenectomized
recipients were not significantly different. Four splenectomized
and five nonsplenectomized allograft recipients had had rejec-
tion episodes before vaccination.
The geometric mean (GM) serum antibody concentration was
calculated for each patient before and after vaccination. The
grand GM antibody concentration was calculated for each
patient group utilizing all 12 type-specific antibody determina-
tions. Student's t test, x2 analysis of covariance, and multiple
regression analysis were used for data processing.
Results
Among the 14 normal volunteers, only 2 (14%) had GM serum
antibody concentrations before vaccination less than 200 ng
N/mI. Serum antibody concentrations after vaccination were
greater than 200 ng N/mI in all 14 subjects. There was a direct
relationship between antibody concentrations before and after
vaccination (r = 0.978, P < 0.001). All but one (93%) achieved
at least a twofold rise in serum antibody concentrations after
vaccination (Fig. 1).
Among chronic renal failure patients, the GM serum antibody
concentration before and after vaccination was not significantly
GM antibody level prevaccination,ngN/m/
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Table 3. Geometric mean serum antibody concentrations before and after vaccination and percent of patients in the different groups responding
to vaccination
Patient group
Geometric mean antibody levela, ng N/mi
% Responderst'Before vaccine After vaccine
Normal
Chronic renal failure
Chronic hemodialysis
Splenectomized allograft recipients
Nonsplenectomized atlograft recipients
313 (253 to 287)
328 (210 to 514)
252 (170 to 374)
158 (106 to 236)C
67 ( 21 to 214)C
1113 (937 to 1323)
664 (287 to 1538)
754 (510 to 1116)
557 (412 to 753)C
370 (150 to 909)C
93
43
79
78
95% confidence index
b Responders include patients with at least a twofold rise in serum antibody concentration after vaccination and a GM postvaccination antibody
concentration greater than 200 ng N/mI.
P < 0.05 (compared with normal subjects).
Table 4. Percentage of patients showing at least a twofold rise in antibody concentrations after vaccination and a GM antibody concentration
postvaccination greater than 200 ng N/ml to each capsular antigen tested
Chronic
Capsular
type Normal
renal
failure
Chronic
hemodialysis
Allograft,
splenectomized
Recipients
splenectomized
1 35 28 35 28 54
3 93 57 71 50 36
4 57 43 50 57 64
6A 64 43 35 57 36
7 64 28 50 64 64
8 93 71 43a 78 54
9 93 57 78 86 73
12 43 14 28 21 9
14 50 43 43 43 64
18 57 14 57 57 54
19 43 28 28 14 27
23 93 57 57 43 27a
p < 0.05 (compared with normal subjects)
different from normal subjects (Table 3). All 7 chronic renal
failure patients had antibody concentrations greater than 200 ng
N/mi before vaccination, although 1 patient had an antibody
concentration after vaccination less than 200 ng N/mi. There
was a direct relationship between the antibody concentrations
before and after vaccination (r = 0.888, P < 0.001). Although
only 3 of the 7 chronic renal failure patients (43%) achieved at
least a twofold rise in antibody concentration after vaccination,
this was of borderline significance (P = 0.09) compared with
controls (Fig. 1). The percentage of chronic renal failure
patients showing at least a twofold rise in antibody concentra-
tion after vaccination and a GM antibody concentration after
vaccination greater than 200 ng N/mi to each capsular antigen
tested was not significantly different from normal subjects
(Table 4).
Chronic hemodialysis patients had a GM serum antibody
concentration before and after vaccination statistically not
different from normal controls (Table 3). Of these 14 patients, 4
(29%) had antibody concentrations before vaccination less than
200 ng N/mi, but none had antibody concentrations after
vaccination below this level. There was a direct relationship
between the serum antibody concentrations before and after
vaccination (r = 0.880, P < 0.001). Of these 14 patients, 11
(79%) achieved at least a twofold rise in antibody concentration
after vaccination (Fig. 1). Fewer hemodialysis patients than
normals responded to type 8 capsular polysaccharides (Table
4).
Renal ailograft recipients had a significantly lower GM serum
antibody concentration before vaccination than normal controls
did (Table 3). Of 14, 8 (57%) splenectomized and 7 of 11(64%)
nonsplenectomized allograft recipients had antibody concentra-
tions before vaccination below 200 ng N/mi (Fig. 1). Among
splenectomized allograft recipients, there was a direct relation-
ship between the serum antibody concentration before vaccina-
tion and the interval between transplantation and serum anti-
body determination (P = 0.04) (Fig. 2). A relationship of similar
statistical significance was not observed for the nonsplenecto-
mized group (P = 0.14). There was no correlation between the
prevaccination antibody level and the dose of immunosuppres-
sive drugs, number of rejection episodes, or the interval be-
tween last rejection and serum antibody determination. After
vaccination, the GM antibody concentration was significantly
lower in renal allograft recipients than it was in normals. One
splenectomized and four nonsplenectomized patients had anti-
body concentrations after vaccinations less than 200 ng N/mI
(Fig. 1). There was a direct relationship between the antibody
concentrations before and after vaccination for spienectomized
(r = 0.909, P < 0.001) and nonspienectomized (r = 0.878, P <
0.001) ailograft recipients. The relationship between the GM
serum antibody concentration after vaccination and the interval
between transplantation and vaccination was not statistically
significant for either spienectomized or nonsplenectomized
allograft recipients (P = 0.12, P = 0.11, respectively). Of the
splenectomized and the nonspienectomized recipients, 78% and
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Fig. 2. Relationship between the geometric mean (GM) serum antibody
concentration before vaccination and the interval between transplanta-
tion and prevaccination serum antibody determination. Dashed area
represents serum antibody concentrations prevaccination in normal
subjects 2 SD. (0 denotes splenectomized renal allogralt recipients;
•, nonsplenectomized renal allograft recipients).
55%, respectively, achieved at least a twofold rise in antibody
concentration after vaccination and had a postvaccination anti-
body concentration greater than 200 ng N/mi. Splenectomized
allograft recipients responded less often to pneumococcai cap-
sular antigen type 23 than did normals, and nonspienectomized
recipients responded less often to capsular types 3 and 23 than
did normal subjects (Table 4).
Of the 26 patients contacted after vaccination, 3 reported
local pain at the site of injection lasting 24 to 36 hours. Three
patients reported local erythema. Serum creatinine determina-
tions after vaccination in renal allograft recipients were not
significantly different from the prevaccination concentrations.
Discussion
These results indicate that patients on chronic hemodialysis
have normal pneumococcal capsular antibody concentrations in
serum before and after vaccination and show a normal rise in
serum antibody concentration after vaccination. Uremic pa-
tients have normal pneumococcal antibody concentrations be-
fore and after vaccination, but less than half achieve a twofold
rise in antibody concentration after vaccination. Our renal
allograft recipients had significantly reduced serum antibody
concentrations before, as well as after vaccination, although
prevaccination serum antibody concentrations in splenecto-
mized patients were directly related to the interval between
transplantation and serum antibody determinations.
Two parameters of response to pneumococcal vaccine were
considered in the data analysis: the amount of rise in serum
antibody concentration after vaccination, and the geometric
mean of 12 individual serum antibody concentrations after
vaccination. The amount of rise (fold rise) in antibody after
vaccination is an index of antibody synthesis after exposure to
antigen but may not reflect the degree of protection achieved.
Although the minimum level of serum pneumococcal antibody
necessary to provide protection is not known, cumulating
information from vaccinated patients who have subsequently
developed pneumococcal disease indicates that serum antibody
concentrations less than 200 ng N/mI may not prevent pneumo-
coccal bacteremia and pneumonia (0. Schiffman, unpublished
observation). Thus, patients who had, after vaccination, at least
a twofold rise in serum antibody concentration, with a geomet-
ric mean greater than 200 ng N/mi, were considered to have had
an adequate protective response. Although these values are
somewhat arbitrary, the same index of response was applied to
each capsular antigen and to each patient group.
Chronic renal failure patients had an impaired antibody
synthesis after vaccination. But, 86% had antibody concentra-
tions after vaccination that were greater than the minimal
protective level. The patient who had a decline in antibody
concentration after vaccination with a postvaccination antibody
concentration less than 200 ng N/mI had a marked deterioration
of renal function after vaccination, unrelated to the vaccine.
Vaccination of uremic patients with various agents has yielded
conflicting results. Uremic patients have shown adequate anti-
body synthesis in respone to immunization with tetanus toxoid
Ill], diphtheria toxoid [12], and killed influenza vaccine [13],
but decreased antibody responses to flagellar and somatic
antigens of Salmonella typhosa [14].
In contrast to our findings, others have found lower pneumo-
coccal antibody concentrations in chronic hemodialysis pa-
tients than they found in normal subjects [15, 16], and in one
study, patients on dialysis showed decreased antibody synthe-
sis after pneumococcal vaccine administration [15]. Several
factors might explain these discrepant results: frequency of
dialysis, time on dialysis, and concentrations of creatinine and
urea nitrogen in blood.
The low serum antibody concentrations found in renal allo-
graft recipients were most likely secondary to the high doses of
immunosuppressive medications given after transplantation.
Dailey et al found normal serum antibody concentrations in
renal allograft recipients [16]. Their patients were studied more
than 6 months after transplantation and did not receive antilym-
phocyte globulin (Rytel, personal communication). Our renal
allograft recipients received local graft radiation after transplan-
tation and during rejection episodes. Siber et al found in
Hodgkin's disease patients that depression of serum antibody
was related to the use of total nodal radiation but not to
localized radiation [17]. The lack of correlation between the
serum antibody concentration before vaccination, the number
of rejection episodes, and the interval between last rejection
and vaccination suggests that the local radiation received by
these patients was not responsible for the serum antibody
depression.
In our patients, the prevaccination antibody concentration
was directly related to the interval between transplantation and
vaccination in splenectomized but not in nonsplenectomized
allograft recipients, suggesting that the spleen may reduce the
effect of immunosuppressive medications on serum antibody
concentration during the early posttransplant period. Because
the postvaccination concentration was directly related to the
prevaccination antibody concentration, one would have expect-
ed that recently transplanted splenectomized patients would
have had a reduced postvaccination antibody concentration.
But, such a reduction was not observed and antibody synthesis
after vaccination was not different in splenectomized and
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nonspienectomized patients, confirming previous reports of
normal antibody synthesis in nonimmunosuppressed splenecto-
mized patients [18—20]. The small number of splenectomized
patients we vaccinated within 12 months of transplantation may
have impaired our ability to detect a difference in postvaccina-
tion antibody concentrations between splenectomized and
nonspienectomized patients. Our patients were not followed
longitudinally, and the relationship between prevaccination
antibody concentration and postvaccination interval may have
represented intrinsic differences among patients.
Although vaccine efficacy in prophylaxis was not studied,
these results suggest that pneumococcal vaccine may be useful
in preventing pneumococcal disease among patients on chronic
hemodialysis. Patients with severe renal failure may have
reduced antibody synthesis after pneumococcal vaccination,
and prophylaxis in these patients might also include antimicro-
bial agents. Renal allograft recipients may be at increased risk
of pneumococcal disease due to their low antibody concentra-
tions. Vaccination of these patients may be useful in increasing
antibody concentration to a protective level. Antimicrobial
prophylaxis may be indicated during periods of greatest risk,
such as early posttransplantation when the antibody concentra-
tions are low and for splenectomized patients.
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